The NMP22™ BladderChek™ Test is a fast, easy to use and non-invasive test that aids in the diagnosis and monitoring of bladder cancer, in conjunction with standard diagnostic …

The Alere NMP22 ® Test Kit is an enzyme immunoassay (EIA) for the in vitro quantitative determination of the nuclear mitotic apparatus protein (NuMA) in stabilized voided urine. …

The NMP22 BladderChek test shows good discrimination ability for detecting bladder cancer and a high-specificity algorithm that can be used for early detection to rule out patients with higher …

NMP22 is one of many nuclear matrix proteins, which specifically exists in urothelial cells. The content of NMP22 in cancerous urothelial cells is 80 times higher than that in normal cells . …

This study was designed to determine the clinical use of NMP22 as a urinary marker for the early detection of transitional cell carcinoma of the bladder in patients with hematuria or other …

A NMP22 test might be a useful adjunct to urine cytology. NMP22 outcomes are affected by haematuria, infection and concentrated urine. NMP22 alone cannot be recommended for …

NMP22 is a tumor marker for bladder cancer. NMP22 is the abbreviated form of Nuclear Matrix Protein Number 22. [1] [2] [3] It reflects the mitotic activity of cells.

The Nuclear Matrix Protein 22 (NMP22) Test is a diagnostic pathology test used to detect the presence of Nuclear Matrix Protein 22 in the urine. NMP22 is a protein biomarker that has …

NMP 22 is a method of cancer detection approved by the FDA and CE. It is known as “NMP 22 bladder check” on commercial grounds. The process is convenient and quick because results …

In this study, we investigated the efficacy of nuclear matrix protein 22 (NMP22) in the diagnosis and surveillance of bladder cancer. Patients with hematuria or who applied for cystoscopic …